Microneedle Flu Vaccine Market Surge in Demand from Healthcare Industry to Boost Growth Forecast to 2026
Vaccine is one of
the most important biologic product used to prevent from infection of
various diseases such as seasonal influenza, hepatitis, polio,
diphtheria, Japanese encephalitis, measles, meningococcal disease,
tetanus, haemophilus influenza type b, whooping cough among others.
Vaccine consists of inactivated or killed form of microorganism or
its protein. Vaccine generates anti-body response, which stimulates
the immune system against specific diseases. Any future infections
due to microorganism can be prevented by vaccinating the patients
against that specific disease. Most of the vaccines are delivered
through conventional needle and syringes, which has certain
challenges such as needle phobia, discomfort in older and pediatric
populations, requirement of special storage infrastructure, and need
to visit the healthcare facility for its administration.
Get Exclusive
Sample Report at: http://bit.ly/2XWmyV4
Microneedle flu
vaccine resolves most of the challenges caused with conventional
vaccines. It is of bandage-strip sized patch, which can be easily
applied all over the skin. It consists of 100 solid water-soluble
needles, which are capable to penetrate skin. Vaccine is encapsulated
in the needles and is released as the needle tip dissolves within
minutes, once the patch is applied over the skin surface. Skin
produces local immune response against pathogens in the vaccine
thereby, providing response similar to that of needle-based vaccine.
The patch is peeled away and discarded like a used bandage strip.
Microneedle Flu
Vaccine Market - Market Dynamics
Microneedle flu
vaccine is still in nascent stage of development however, after its
launch it would provide various advantages over conventional
needle-based vaccines, which will drive growth of the market.
Microneedle vaccine
can be delivered easily at any location without special storage
infrastructure, therefore it can be used even at distant location.
This vaccine can be self-administered by anybody thereby, eliminating
the need of clinic visit and assistance of physician. This serves as
an important advantage, especially in the emerging markets, where
there is severe shortage of healthcare workers. According to World
Health Organization, 2017 factsheet, Africa had an average of 1.30
health workers per 1000 population in 2015, which is way below the
4.5 per 1000 required for achievement of Sustainable Development
Goals (SDGs). Globally, health workforce shortage is estimated to be
14.5 million, out of which Africa has the most severe health
workforce (HWF) shortage, estimated to reach 6.1 million by 2030.
Microneedle vaccine can address these issues if utilized on global
scale. Moreover, it would avoid deaths caused from unavailability of
vaccine by improving access to vaccination. For instance, according
to United Nations Development Programme, measles vaccines have
averted nearly 15.6 million deaths since 2000, globally.
Microneedle vaccines
are safe and without any serious life threatening or adverse effects.
These vaccines do not create sharp waste, thereby eliminating the
problem of discarding needles. Patients suffering with needle phobia
can easily use microneedle flu vaccine. According to a study
published in Behavioral Neurology, 2014, around 3-4% of the world
population faces needle phobia. This impacts their hospital or clinic
visits, as they avoid visiting such facilities due to fear of
exposure to needles. Needle phobia also impacts the vaccination
amongst children, as most of them perceives injecting vaccine as a
painful procedure. According to a study published in the Clinical
Journal of Pain in 2015, there were 12 billion vaccination every year
worldwide, most of which required injecting drug with a needle
syringe system. Microneedle vaccine could reduce overall cost of
vaccination.
However, there are
certain limitations in the development of microneedle flu vaccine
market such as problem in commercialization due to limited investment
in scalable aseptic manufacturing, once product is completed with
development stage.
Microneedle Flu
Vaccine Market – Regional Insights.
On the basis of
geography, the global microneedle flu vaccine market is segmented
into North America, Latin America, Europe, Asia Pacific, Middle East,
and Africa. North America would be dominant region in the global
microneedle flu vaccine market during the forecast period. This is
owing to the need of large number of influenza vaccines each year and
current ongoing research over microneedle flu vaccine in the region.
In June 2017, National Institutes of Health-funded study led by a
team at the Georgia Institute of Technology and Emory University
published a report in the journal Lancet, which shows that an
influenza vaccine can produce robust immune responses and be
administered safely with an experimental patch of dissolving
microneedle. Participants in the study preferred microneedle flu
vaccine over other types of vaccines.
There is increased
amount of research funding to develop commercially available micro
needle flu vaccine, which would pace up the launch of these products.
In 2015, the Georgia Institute of Technology and Micron Biomedical
were awarded US$ 2.5 million in grants from the Bill & Melinda
Gates Foundation to advance the development of dissolvable
microneedle patches for polio immunization. This would also widen up
the disease profile for which microneedle vaccine could be developed.
Growing instances of
influenza flu pandemics in the U.S. would promote faster development
of microneedle vaccines with reduced vaccination cost and no special
need of storage conditions. According to Centers for Disease Control
and Prevention, February 2018 report, during October 2017 and
February 2018, clinical laboratories tested 666,493 specimens for
influenza virus, 124,316 (18.7%) of which tested positive for
influenza virus and 84.3% tested positive for influenza A virus.
Ask For Discount
Before Purchasing This Business Report @ http://bit.ly/2Zxcu5w
Key players in
the global microneedle flu vaccine market are Micron Biomedical,
Microdermics Inc., 3M Company, Inc., VaxInnate, and Vetter among
others.
Microneedle Flu
Vaccine Market Taxonomy
On the basis of
vaccine type, the global microneedle flu vaccine market is segmented
into:
Trivalent Flu
Vaccine
Quadrivalent Flu
Vaccine
On the basis of
virus type, the global microneedle flu vaccine market is segmented
into:
Influenza Virus
Type- A
Influenza Virus
Type- B
On the basis of
geography, the global microneedle flu vaccine market is segmented
into:
North America
Latin America
Europe
Asia Pacific
Middle East
Africa
About Coherent
Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Comments
Post a Comment